Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Cher

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Neuro-Oncology|March 19, 2013
Rituximab is associated with improved survival for aggressive B cell CNS lymphomaGareth Gregory, Ashwini Arumugaswamy, Teresa Leung, et al.
Nuclear Medicine and Biology|February 2, 2002
Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO)Henri J Tochon-Danguy, John I Sachinidis, Fiona Chan, et al.
Journal of Neuro-Oncology|May 24, 2017
Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastomaKathryn M Field, Madeleine T King, John Simes, et al.
Neuro-Oncology Practice|August 7, 2019
Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trialElizabeth J Hovey, Kathryn M Field, Mark A Rosenthal, et al.
Clinical and Translational Radiation Oncology|February 27, 2026
Clinical outcomes and quality of life in glioblastoma patients treated with MR-guided adaptive radiotherapy using a 1.5 T MR-Linac in an Australian settingKurl Jamora, Morikatsu Wada, Richard Khor, et al.
Asia-Pacific Journal of Clinical Oncology|November 9, 2017
Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trialKathryn M Field, Greg Fitt, Mark A Rosenthal, et al.
Neuro-Oncology|July 2, 2015
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastomaKathryn M Field, John Simes, Anna K Nowak, et al.
Clinical and Translational Radiation Oncology|June 22, 2026
Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear acceleratorKurl Jamora, Dominique Mathieu, Su Chen Fong, et al.
Asia-Pacific Journal of Clinical Oncology|June 5, 2025
Identification of Clinical Variation of Interest in Standard of Care Practice in a Statewide Bench Marking Audit of Brain Tumor Patient CareHui K Gan, Laura Tam, Janine Scott, et al.
Neuro-Oncology|February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastomaAlba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Neuro-Oncology|March 19, 2013
Rituximab is associated with improved survival for aggressive B cell CNS lymphomaGareth Gregory, Ashwini Arumugaswamy, Teresa Leung, et al.
Nuclear Medicine and Biology|February 2, 2002
Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO)Henri J Tochon-Danguy, John I Sachinidis, Fiona Chan, et al.
Journal of Neuro-Oncology|May 24, 2017
Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastomaKathryn M Field, Madeleine T King, John Simes, et al.
Neuro-Oncology Practice|August 7, 2019
Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trialElizabeth J Hovey, Kathryn M Field, Mark A Rosenthal, et al.
Clinical and Translational Radiation Oncology|February 27, 2026
Clinical outcomes and quality of life in glioblastoma patients treated with MR-guided adaptive radiotherapy using a 1.5 T MR-Linac in an Australian settingKurl Jamora, Morikatsu Wada, Richard Khor, et al.
Asia-Pacific Journal of Clinical Oncology|November 9, 2017
Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trialKathryn M Field, Greg Fitt, Mark A Rosenthal, et al.
Neuro-Oncology|July 2, 2015
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastomaKathryn M Field, John Simes, Anna K Nowak, et al.
Clinical and Translational Radiation Oncology|June 22, 2026
Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear acceleratorKurl Jamora, Dominique Mathieu, Su Chen Fong, et al.
Asia-Pacific Journal of Clinical Oncology|June 5, 2025
Identification of Clinical Variation of Interest in Standard of Care Practice in a Statewide Bench Marking Audit of Brain Tumor Patient CareHui K Gan, Laura Tam, Janine Scott, et al.
Neuro-Oncology|February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastomaAlba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
Pageof 4